The results showed that there was a significant difference in overall survival (P = 0.004), progression-free interval (P = 0.004), and disease-specific survival (P = 0.001) between the pancreatic cancer patients in the high and low RAB7A expression groups. The gene discussed is RAB7A; the disease is pancreatic neoplasm.